| Range: | 1.88-33.89 | Vol Avg: | 5129400 | Last Div: | 0 | Changes: | -1.14 |
| Beta: | -0.92 | Cap: | 13.50B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Mar 05 2015 | Empoloyees: | 105 | ||
| CUSIP: | 86627T108 | CIK: | 0001599298 | ISIN: | US86627T1088 | Country: | US |
| CEO: | Mr. Robert W. Duggan | Website: | https://www.summittxinc.com | ||||
SMMT 19.30 Stock Price Summit Therapeutics Inc.
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also offers SMT-738, for combating multidrug resistant infections primarily carbapenem-resistant Enterobacteriaceae infections; and DDS-04 series for the potential treatment of infections caused by the Enterobacteriaceae. The company was founded in 2003 and is based in Cambridge, Massachusetts.
Stock Details
Neutral 0.00
Why Summit Therapeutics Stock Was a Winner Today
A cancer drug has vast potential for the company, says a pundit newly following it....
fool.com·Mon Nov 04 2024
Positive 0.11
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Summit Therapeutics Inc. NASDAQ: SMMT is a development-stage biotech company specializing ...
marketbeat.com·Mon Nov 04 2024
Positive 0.34
Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript
Summit Therapeutics Inc. (NASDAQ:SMMT ) Q3 2024 Earnings Conference Call October 30, 2024 ...
seekingalpha.com·Wed Oct 30 2024
Neutral 0.00
Is Summit Therapeutics a Millionaire Maker?
The potential upside of this stock is undeniably meaty....
fool.com·Sun Oct 27 2024
Neutral 0.10
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?
This drugmaker's lead candidate could become a top-selling cancer therapy....
fool.com·Thu Oct 24 2024
Positive 0.20
Up 700% This Year, Is It Too Late to Invest in This Stock?
The shares have experienced a pullback in the past couple of weeks....
https://www.fool.com/investing/2024/10/15/up-700-this-year-is-it-too-late-to-invest-in-this/·Tue Oct 15 2024
Neutral 0.06
Is Summit Therapeutics a Millionaire Maker?
This company's promising cancer drug could challenge Merck's $25 billion crown jewel....
fool.com·Sat Oct 05 2024
Neutral 0.00
Could Summit Therapeutics Become the Next Merck?
Recent developments are forcing comparisons between these two drugmakers....
fool.com·Fri Oct 04 2024
Neutral 0.00
Where Will Summit Therapeutics Be in 3 Years?
There's a lot riding on how its collaborator's studies end up performing....
fool.com·Thu Oct 03 2024
Positive 0.40
Has Summit Therapeutics Stock Already Peaked?
Summit Therapeutics stock is up a remarkable 700% this year....
fool.com·Wed Oct 02 2024
Positive 0.30
Is Summit Therapeutics Stock a Buy?
Summit Therapeutics is having a great year, and it could realize revenue soon. Its partner...
fool.com·Mon Sep 30 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow